A pioneering new scheme in the United States is set to dramatically alter the landscape of affordable healthcare for millions of older Americans struggling with their weight. From July, the 'Medicare GLP-1 Bridge' initiative will make three popular weight-loss drugs – Foundayo, Wegovy, and Zepbound – available to eligible individuals aged 65 and over at a substantially reduced cost of just $50 (approximately £39.50) per month.
The programme, administered by the Centers for Medicare & Medicaid Services (CMS), aims to alleviate the financial burden faced by many seniors who currently cannot afford these medications, which can cost hundreds of dollars a month. For Kathryn, a 66-year-old retiree from Denver, Colorado, the current monthly price tag of around $450 (£355) has meant making tough choices about her retirement plans due to her lifelong weight struggles.
While experts welcome the initiative's potential to improve health outcomes and provide financial relief, they are also highlighting significant concerns. Dr Annie Moore, an internist at CU Health in Denver, describes it as a "huge social and healthcare experiment," citing worries that the federal government, pharmacies, and health systems may struggle to process the anticipated surge in prior authorisations.
The expected increase in demand is particularly worrying given global supply chain pressures. The National Health Service (NHS) has already experienced intermittent shortages of GLP-1 medications, used for both type 2 diabetes and weight management, with some patients reporting difficulties accessing their prescriptions. A significant rise in US demand could exacerbate these shortages, potentially affecting the availability of these drugs for UK patients and putting additional pressure on NHS procurement budgets.
The programme's temporary nature until the end of 2027 is another concern. Obesity is a chronic condition, and patients typically regain weight if they cease taking GLP-1 medications. This raises questions about the long-term sustainability of the scheme and its potential impact on patient health outcomes.